Odanacatib, an Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
EDINBURGH, Scotland–(BUSINESS WIRE)–June 30, 2008–Merck & Co.,
Inc, Whitehouse Station, NJ, USA, which operates in many countries as
Merck Sharp & Dohme or MSD, announced results of a new study in which
its investigational selective cathepsin K inhibitor odanacatib reduced
measures of bone turnover (breakdown and rebuilding of bone) in women
with breast cancer that has […]